Physician
Cmcla Pathology Medical Group
Cmcla Pathology Medical Group was paid $3.42M by Medicaid between Jan 2018 and Nov 2024, across 145 billing codes. Its largest line is 88305, Level IV - Surgical pathology, gross and microscopic examination — 17% of everything it billed.
33Billing provider infoCMCLA PATHOLOGY MEDICAL GROUP
LOS ANGELES, CA 90015
LOS ANGELES, CA 90015
33aNPI1316970932assigned 07/08/2006
33bProvider typeAnatomic Pathology & Clinical Pathology Physician
28Total paid$3.42M
24GClaims1,798,814
24DCodes billed145
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Anatomic Pathology & Clinical Pathology Physician providers in California
Rank by total paid#15 of 222
Median peer was paid$42K
This provider vs. median81×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 251,630 | $348K | |
| 2019 | 263,847 | $508K | |
| 2020 | 236,759 | $490K | |
| 2021 | 288,913 | $552K | |
| 2022 | 258,853 | $556K | |
| 2023 | 292,306 | $622K | |
| 2024incomplete | 206,506 | $348K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 17% | 18,232 | 17,578 | $566K |
| 80053 | Comprehensive metabolic panel | 11% | 240,197 | 125,561 | $366K |
| 88307 | 10% | 7,189 | 7,070 | $355K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 6.5% | 214,983 | 126,790 | $221K |
| 88312 | 4.9% | 6,982 | 6,894 | $169K | |
| 83880 | 4.4% | 37,461 | 33,680 | $150K | |
| 83735 | 3.0% | 102,656 | 35,243 | $102K | |
| 85027 | 3.0% | 106,879 | 57,009 | $101K | |
| 88304 | 2.7% | 5,469 | 5,405 | $91K | |
| 83690 | 2.4% | 79,834 | 69,837 | $81K | |
| 84484 | 2.3% | 55,030 | 45,916 | $77K | |
| 80048 | Basic metabolic panel (calcium, ionized) | 2.0% | 57,144 | 28,505 | $70K |
133 more codes
| 85730 | 1.8% | 68,358 | $62K | |
| 86803 | 1.8% | 34,770 | $61K | |
| 81001 | 1.6% | 82,307 | $54K | |
| 87040 | 1.5% | 24,007 | $51K | |
| 84145 | 1.5% | 15,361 | $50K | |
| 85610 | 1.4% | 71,861 | $48K | |
| 85007 | 1.4% | 73,599 | $47K | |
| 83605 | 1.1% | 21,152 | $39K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 1.1% | 9,034 | $38K |
| 86703 | <1% | 19,491 | $32K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 2,634 | $28K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 12,736 | $27K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 6,260 | $26K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 24,956 | $25K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 17,846 | $24K |
| 80061 | Lipid panel | <1% | 12,821 | $23K |
| 80074 | <1% | 4,249 | $23K | |
| 86900 | <1% | 36,085 | $20K | |
| 86850 | <1% | 24,931 | $19K | |
| 86901 | <1% | 35,993 | $18K | |
| 87340 | <1% | 13,451 | $17K | |
| 84702 | <1% | 9,348 | $16K | |
| 87081 | <1% | 14,331 | $15K | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 1,749 | $15K |
| 86592 | <1% | 17,829 | $15K | |
| 88342 | <1% | 528 | $13K | |
| 80202 | <1% | 7,183 | $12K | |
| 86140 | <1% | 16,182 | $12K | |
| 88341 | <1% | 272 | $12K | |
| 87077 | <1% | 8,966 | $11K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 1,658 | $11K |
| 81003 | <1% | 18,883 | $10K | |
| 82247 | <1% | 12,343 | $9K | |
| 83615 | <1% | 9,635 | $8K | |
| 87522 | Neg quan hep c or qual rna | <1% | 1,615 | $8K |
| 87631 | <1% | 1,101 | $8K | |
| 87186 | <1% | 6,333 | $8K | |
| 82728 | <1% | 4,267 | $7K | |
| 82248 | <1% | 12,377 | $7K | |
| 87070 | <1% | 5,349 | $7K | |
| 82553 | <1% | 3,914 | $7K | |
| 82140 | <1% | 3,238 | $6K | |
| 82570 | <1% | 6,950 | $6K | |
| 86759 | <1% | 2,785 | $6K | |
| 88302 | <1% | 298 | $6K | |
| 85380 | <1% | 6,306 | $5K | |
| 82746 | <1% | 2,673 | $5K | |
| 87205 | <1% | 6,792 | $5K | |
| 84133 | <1% | 6,624 | $5K | |
| 88300 | <1% | 820 | $4K | |
| 89051 | <1% | 1,579 | $4K | |
| 87147 | <1% | 2,785 | $4K | |
| 82607 | <1% | 2,023 | $4K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 2,900 | $3K |
| 84439 | <1% | 2,938 | $3K | |
| 88313 | <1% | 119 | $3K | |
| 87210 | <1% | 5,276 | $3K | |
| 83540 | <1% | 3,396 | $3K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 3,259 | $3K |
| 84703 | <1% | 2,402 | $3K | |
| 83550 | <1% | 2,331 | $3K | |
| 86880 | <1% | 3,066 | $2K | |
| 85045 | <1% | 3,518 | $2K | |
| 85651 | <1% | 3,922 | $2K | |
| 88329 | <1% | 142 | $2K | |
| 83498 | <1% | 519 | $2K | |
| 80076 | <1% | 1,595 | $2K | |
| 84300 | <1% | 2,271 | $2K | |
| 87088 | <1% | 1,568 | $2K | |
| 87506 | <1% | 61 | $1K | |
| 86762 | <1% | 783 | $1K | |
| 86706 | <1% | 808 | $1K | |
| 83789 | <1% | 508 | $1K | |
| 83021 | <1% | 527 | $1K | |
| 82261 | <1% | 519 | $1K | |
| 83930 | <1% | 1,096 | $1K | |
| 84478 | <1% | 1,348 | $1K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 389 | $911.70 |
| 87451 | <1% | 347 | $792.09 | |
| 88112 | <1% | 66 | $791.85 | |
| 87449 | <1% | 535 | $669.00 | |
| 83516 | <1% | 517 | $637.62 | |
| 87073 | <1% | 680 | $627.56 | |
| 82776 | <1% | 518 | $595.64 | |
| 82565 | <1% | 454 | $593.30 | |
| 86481 | <1% | 62 | $569.10 | |
| 82009 | <1% | 714 | $566.79 | |
| 82550 | <1% | 699 | $548.94 | |
| 83935 | <1% | 542 | $532.41 | |
| 82150 | <1% | 414 | $464.16 | |
| 85018 | <1% | 1,049 | $432.99 | |
| 80170 | <1% | 171 | $428.02 | |
| 88311 | <1% | 96 | $414.12 | |
| 89050 | <1% | 198 | $394.72 | |
| 84481 | <1% | 180 | $377.99 | |
| 84100 | <1% | 493 | $364.70 | |
| 85014 | <1% | 1,078 | $362.92 | |
| 87420 | <1% | 764 | $357.37 | |
| 86038 | <1% | 229 | $298.33 | |
| 80185 | <1% | 134 | $243.67 | |
| 87045 | <1% | 204 | $223.43 | |
| 81005 | <1% | 681 | $213.02 | |
| 87324 | <1% | 157 | $192.21 | |
| 86361 | <1% | 43 | $146.13 | |
| 84112 | <1% | 396 | $144.57 | |
| 86689 | <1% | 56 | $144.40 | |
| 84132 | <1% | 221 | $131.30 | |
| 87046 | <1% | 187 | $127.55 | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 27 | $105.99 |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 60 | $103.43 |
| 87634 | <1% | 13 | $102.73 | |
| 82731 | <1% | 13 | $78.68 | |
| 82310 | <1% | 157 | $75.07 | |
| 84466 | <1% | 41 | $69.46 | |
| 86870 | <1% | 27 | $66.88 | |
| 80305 | <1% | 27 | $65.62 | |
| 82239 | <1% | 20 | $63.57 | |
| 87116 | <1% | 37 | $62.98 | |
| 82378 | <1% | 24 | $55.87 | |
| 82042 | <1% | 74 | $54.12 | |
| 86160 | <1% | 15 | $53.72 | |
| 86769 | <1% | 13 | $51.48 | |
| 86704 | <1% | 28 | $45.07 | |
| 80047 | <1% | 37 | $43.99 | |
| 82533 | <1% | 14 | $38.86 | |
| 85347 | <1% | 64 | $38.73 | |
| 82945 | <1% | 85 | $30.06 | |
| 82947 | <1% | 67 | $24.37 | |
| 86920 | <1% | 14 | $21.29 | |
| 86593 | <1% | 41 | $20.61 | |
| 80050 | General health panel | <1% | 35 | $13.01 |
| 87899 | <1% | 27 | $10.84 | |
| 80320 | <1% | 14 | $7.30 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialNACHAZEL, JOHN (PATHOLOGIST/OWNER)